Immedica presents data at AES related to recent FDA approval of updated ZTALMY® (ganaxolone) label, highlighting the new 28-day titration schedule

Chicago, IL, December 10, 2025 – At the American Epilepsy Society (AES) 2025 Annual Meeting this week, Immedica Pharma US Inc. presented data that supports the recent United States Food and Drug Administration (FDA) update to the ZTALMY® (ganaxolone) label.  ZTALMY is indicated for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients two years of age and older. “Revising the ZTALMY titration schedule has the potential to improve ZTALMY tolerability during the up-titration period with respect to the somnolence-related